Edward Imbrogno Net Worth

Edward Imbrogno biography

Edward Imbrogno serves as Chief Financial Officer, Chief Accounting Officer, Vice President - Finance of the Company. From May 2017 to October 2018, Mr. Imbrogno was Senior Director and Corporate Controller for BioDelivery Sciences International, Inc., a Nasdaq-listed specialty pharmaceutical company. From June 2016 to April 2017, Mr. Imbrogno provided accounting and financial reporting consulting services. From September 2013 to May 2014, Mr. Imbrogno was Vice President, Financial Reporting for International Lease Finance Corporation, the world’s largest independent aircraft lessor, until its acquisition by AerCap Holdings N.V. Mr. Imbrogno remained with AerCap through March 2016 assisting with post-acquisition financial reporting transition, primarily at AerCap’s headquarters in Amsterdam, Netherlands. From 2006 to 2013, he was Director, Accounting for Amgena Nasdaq-listed multinational biopharmaceutical company. Prior to Amgen, Mr. Imbrogno held positions at several companies with increasing financial accounting and reporting responsibilities. Mr. Imbrogno began his career in public accounting with EY culminating as an Audit Manager where he provided audit and related financial services to public and private companies. Mr. Imbrogno holds a B.S. in accounting from Pennsylvania State University and an M.B.A. from Wake Forest University. He is a licensed Certified Public Accountant and is a member of the American Institute of Certified Public Accountants.

What is the salary of Edward Imbrogno?

As the Chief Financial Officer、 Chief Accounting Officer、 Vice President - Finance of PDL Biopharma Inc, the total compensation of Edward Imbrogno at PDL Biopharma Inc is 814,143$. There are 2 executives at PDL Biopharma Inc getting paid more, with Dominique Monnet having the highest compensation of 6,701,000$.

How old is Edward Imbrogno?

Edward Imbrogno is 56, he's been the Chief Financial Officer、 Chief Accounting Officer、 Vice President - Finance of PDL Biopharma Inc since 2020. There are 3 older and 3 younger executives at PDL Biopharma Inc. The oldest executive at PDL Biopharma Inc is John McLaughlin, 68, who is the Director.

Insiders trading at PDL Biopharma Inc

Over the last 22 years, insiders at PDL Biopharma Inc have traded over 45,966,964$ worth of PDL Biopharma Inc stock and bought 12,693,393 units worth 32,804,545$ . The most active insiders traders include Point Capital L.P.O'shea Ro...、Faheem Hasnain、Laurence Jay Korn. On average, PDL Biopharma Inc executives and independent directors trade stock every 24 days with the average trade being worth of 245,074,578$. The most recent stock trade was executed by Point Capital L.P.O'shea Ro... on 1 February 2021, trading 187,061 units of PDLI stock currently worth 383,475$.

What does PDL Biopharma Inc do?

PDL Biopharma Inc executives and stock owners

PDL Biopharma Inc executives and other stock owners filed with the SEC include:

• Dominique Monnet,
  President, Chief Executive Officer, Director
• Christopher Stone,
  Vice President, General Counsel, Secretary
• Edward Imbrogno,
  Chief Financial Officer, Chief Accounting Officer, Vice President - Finance
• John McLaughlin,
  Director
• David Gryska,
  Independent Director
• Elizabeth O'Farrell,
  Chairperson of the Board
• Natasha Hernday,
  Independent Director
• Alan Bazaar,
  Independent Director
• Danny J Jr. Hart,
  Assoc Genl Counsel/Asst Sec
• Samuel R Saks,
  Director
• Jody S Lindell,
  Director
• Paul R Edick,
  Director
• Harold E Selick,
  Director
• Paul W Sandman,
  Director
• Peter S Garcia,
  Vice President, CFO
• Steffen Pietzke,
  Controller and CAO
• Shlomo Yanai,
  Director
• Jill M. Jene,
  VP, Business Development
• Christine R Larson,
  VP & Chief Financial Officer
• Joseph Iii Klein,
  Director
• Karen J Wilson,
  VP of Finance & PAO
• Mark Anthony Mc Camish,
  SVP & CMO
• Brett L Schmidli,
  SVP, Technical Operations
• Gary A Lyons,
  Director
• Andrew Guggenhime,
  SVP & Chief Financial Officer
• Faheem Hasnain,
  President & CEO
• Francis Willard Sarena,
  Exec Dir/Chief Legal Off/Secy
• Herb Cross,
  Corp Controller/Prin Acctg Off
• Richard /Ca/ Murray,
  Sr. VP & CSO
• Steven E Benner,
  SVP and Chief Medical Officer
• Bradford S Goodwin,
  Director
• Laurence Jay Korn,
  Chairman of the Board
• Karen A Dawes,
  Director
• Jaisim Shah,
  Vice President, Marketing
• Jon S Saxe,
  Director
• L Patrick Gage,
  Director
• Glen Y Sato,
  SVP and CFO
• Cynthia Lynn Shumate,
  VP Legal Affrs, Secy & CCO
• Cary L Queen,
  Senior Vice President
• Peter H Calcott,
  VP, Quality & Compliance
• Laurie C Torres,
  VP, Human Resources
• David Iwanicki,
  VP, Sales & Sales Operations
• Mark Mcdade,
  Chief Executive Officer
• Robert Michael Ii Savel,
  SVP Technical Operations
• Samuel Broder,
  Director
• George Jue,
  VP, Fin & Corp. Controller
• Max Link,
  Director
• Sergio Garcia Rodriguez,
  VP, Legal and General Counsel
• Lyn D Olson,
  VP, Quality and Compliance
• Douglas O Ebersole,
  SVP, Legal & Corp Development
• George M Gould,
  Director
• Jurgen Drews,
  Director
• Behrooz Najafi,
  V.P. IS and Corporate Services
• Corine Klingbell,
  VP, Preclinical Development
• William R Benjamin,
  VP, Research & Clinical Tech
• Frances G Charlson,
  VP, Human Resources
• Patrick M Caldwell,
  VP, Finance and Controller
• Mark P Backer,
  VP, Technical Development
• David Montez,
  Controller and CAO
• Fred Frank,
  Director
• Bruce Tomlinson,
  Chief Financial Officer
• Caroline J Krumel,
  Vice President of Finance
• Point Capital L.P.O'shea Ro...,